logo
  

Parker Hannifin Q1 Profit Beats View; Lifts Low End Of 2015 Earnings Outlook

Fluid power systems manufacturer Parker Hannifin Corp. (PH) on Tuesday reported a 15 percent increase in profit for the first quarter from last year, reflecting higher sales and lower expenses.

Adjusted earnings per share for the quarter beat analysts' expectations. Looking ahead, the company raised the low end of its earnings guidance for fiscal 2015.

Don Washkewicz, Chairman, CEO and President of Parker Hannifin said, "As a result of the restructuring activities we engaged in last year, we are beginning to see stronger year-over-year segment operating margin performance, which reached 15.9 percent this quarter, or 16.1 percent adjusted."

The Cleveland, Ohio-based company's first-quarter net income attributable to shareholders was $280.09 million or $1.85 per share, up from $244.32 million or $1.61 per share in the prior-year quarter.

Excluding restructuring expenses, adjusted earnings per share for the quarter were $1.89, compared to $1.67 per share in the same period last year. On average, 16 analysts polled by Thomson Reuters expected the company to report earnings of $1.67 per share in the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter grew 1 percent to $3.27 billion from $3.23 billion in the same quarter last year. Adjusted total net sales, excluding sales related to GE joint venture last year, grew 2.9 percent. Analysts' had a consensus revenue estimate of $3.28 billion.

Industrial North American business reported 6 percent growth in sales from the year-ago period to $1.47 billion, while the industrial international business reported a 1 percent decline in sales to $1.26 billion.

Sales for the company's aerospace business decreased 6 percent to $534.62 million, reflecting the impact of the joint venture between Parker Aerospace and GE Aviation recorded in the prior year's second quarter. Adjusted sales for the segment increased 3.2 percent.

Selling, general and administrative expenses for the quarter were $400.84 million, down 1 percent from last year.

Parker Hannifin's total orders for the quarter grew 5 percent from last year.

Looking ahead to fiscal 2015, Parker Hannifin now forecasts earnings per share from continuing operations in a range of $7.20 to $7.80 per share, or $7.45 to $8.05 per share on an adjusted basis. Earlier, the company forecast earnings in a range of $7.00 to $7.80 per share, or $7.25 to $8.05 per share on an adjusted basis.

Street expects the company to earn $7.67 per share for the year.

The company noted that the revised outlook is adjusted for expected restructuring expenses of about $0.25 per share.

Washkewicz added, "Macroeconomic readings indicate some uncertainty in demand levels, particularly internationally. However, savings resulting from the timely and solid execution of our restructuring activities give us confidence that we can achieve our earnings outlook and deliver a record year."

PH closed Monday's trading at $117.24, up $0.67 or 0.57 percent on a volume of 1.81 million shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT